Brava is developing a NextGen test for heart attack for the emergency department. Our first cardiac marker test is a high-sensitivity troponin (hs-cTn) test that will enable faster diagnosis of heart attack or rule-out/discharge of low-risk patients. Safe discharge reduces unnecessary hospital admissions, reduces crowding in the emergency department and cuts costs to the healthcare system significantly.
Market and Key Drivers
|Market Opportunity||Brava’s Superior Technology||Competitive Advantages|
|The market for cardiac markers will reach $2.45 billion by 2025. The POC segment will reach $806 million by 2025. |
European and US guidelines are driving a shift to high-sensitivity troponin assays to improve diagnosis of heart attack and to discharge low-risk patients safely.
|Our evanescent planar waveguide platform delivers lab-quality results at the point-of-care.|
• Whole blood sample
• Simple test procedure
• Results in <15 minutes compared to >1 hour from the central lab.
Limitations of current POC methods prevent achieving metrics in the guidelines.
|Meets American College of Cardiology and European Society of Cardiology guidelines for sensitivity and precision.
• Sensitivity at pg/mL concentrations
• Precision CV <10% at the 99th percentile of the reference population
Market and Product OVERVIEW
This short video highlights:
- Market drivers for a high-sensitivity troponin test
- The LightDeck Platform
This video gives an overview of the careers of Brava's executive team.
Emergency physicians need precise lab results, ideally within 15 minutes, to guide treatment or safe discharge for patients with chest pain. New guidelines from the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) are driving the shift to high-sensitivity troponin assays (hs-cTn). Central lab tests suffer from turnaround time of more than an hour. Point-of-care (POC) assays are widely used, but the, care team must compromise performance for speed. Neither lab nor POC tests meet the need.
Brava can fill this large market gap with a high-sensitivity troponin test that delivers lab-quality performance at the point-of-care in 15 minutes. Our evanescent planar waveguide technology is a different approach to POC diagnostics that enables a low-cost instrument and high margin consumable cartridges. The platform enables precise measurements at very low concentrations. MBio developed the core technology over ten years and has commercialized products outside of human health, significantly de-risking product development. Brava will build on these accomplishments by adapting the instrument for the healthcare market, developing in vitro diagnostic assays and executing clinical trials.
Download our Fact Sheet
Download a 2-page strategy summary.
Schedule a meeting